MON-LB008 PD-L1 Expression in Normal Endocrine Tissues

Introduction: Immune checkpoint inhibitor (ICI) therapy, including cytotoxic T-lymphocyte-associated protein 4 (CLTA-4) and programmed cell death 1 (PD-1) inhibitors, is revolutionizing cancer treatment. However, these agents are associated with immune-related adverse events (irAEs), most commonly e...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Endocr Soc
Главные авторы: Pollack, Rena, Kagan, Maayan, Dresner-Pollak, Rivka, Tzahi, Neuman
Формат: Artigo
Язык:Inglês
Опубликовано: Endocrine Society 2019
Предметы:
Endocrine Disruption
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6550633/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-LB008
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы